Mei Ri Jing Ji Xin Wen·2025-11-12 23:24Group 1 - The chairman and president of Beijing Medical, Xu Xiren, has been formally arrested for suspected criminal activities, with the company stating that its control and operations remain stable despite the incident [1] - The company is currently facing challenges such as declining revenue and halted progress in its "de-Beijing" strategy, necessitating improvements in governance and a focus on core business to rebuild market confidence [1] Group 2 - Lai Kai Pharmaceutical has signed an exclusive licensing agreement with Qilu Pharmaceutical for the commercialization of the breast cancer candidate drug LAE002 in China, with potential payments totaling up to 2.45 billion yuan [2] - This partnership marks a significant step for Lai Kai Pharmaceutical as it transitions its first innovative drug product into the commercialization phase, establishing a foundation for future research and development [2] Group 3 - Andao Pharmaceutical has completed a C-round financing exceeding 400 million yuan, with investments from various institutions aimed at accelerating the development of its drug pipeline focused on kidney diseases, anemia, and cancer [3] - The funding is expected to fill gaps in the market and provide momentum for the company's growth and innovation in specialized therapeutic areas [3] Group 4 - Shengjian Medical plans to invest approximately 2 billion yuan to establish a production base for all-cotton water-jet non-woven fabric, focusing on high-quality and large-scale production [4] - This investment aligns with trends in sustainable consumption and industrial upgrades, enhancing the company's product matrix and cost advantages for long-term growth [4]